Fueled by the discovery of new biomarkers, personalized medicine will cause diagnostic and pharmaceutical companies to shift their thinking about new products, and eventually perhaps to adopt a radically new business model.

Advances in genomics, proteomics, and metabolomics over the last decade have provided an unprecedented, exquisitely detailed view into the molecular nature of disease and treatment. Biomarkers are among the most practical tools arising from the “omics” revolution.